# Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

> **NCT01347788** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 34 (actual)

## Conditions studied

- Prostate Adenocarcinoma

## Interventions

- **DRUG:** cabozantinib

## Key facts

- **NCT ID:** NCT01347788
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2016-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01347788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01347788, "Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01347788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*